Evidence map›Paper›PMID 26046454›Full record

ArticleEuropean journal of immunology2015

Human group3 innate lymphoid cells express DR3 and respond to TL1A with enhanced IL-22 production and IL-2-dependent proliferation.

Yong-Oon Ahn, Matthew A Weeres, Marie-Luise Neulen, Jahyang Choi, Seong-Ho Kang, Dae Seog Heo, Rachel Bergerson, Bruce R Blazar, Jeffrey S Miller, Michael R Verneris

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 53 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. ILC3: a case of conflicted identity.Frontiers in immunology · 2023
    Review
  14. Review
  15. Review
  16. EfficientFrontiers in immunology · 2021
    Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Yong-Oon AhnDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, USA.
Matthew A WeeresDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, USA.
Marie-Luise NeulenDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, USA.
Jahyang ChoiCancer Research Institute, Seoul National University College of Medicine and Hospital, Seoul, Korea.
Seong-Ho KangCancer Research Institute, Seoul National University College of Medicine and Hospital, Seoul, Korea.
Dae Seog HeoCancer Research Institute, Seoul National University College of Medicine and Hospital, Seoul, Korea.
Rachel BergersonDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, USA.
Bruce R BlazarDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, USA.
Jeffrey S MillerDepartment of Medicine, Division of Blood and Marrow Transplantation, University of Minnesota, USA.
Michael R VernerisDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, USA.
University of Minnesota · USSeoul National University Hospital · KR

Funding

Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2M
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2M
GVL TO REDUCE AML RELAPSE AFTER MURINE ALLOGENEIC BMTR01CA072669 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1997 to 2017
$4.9M
NK Cell Differentiation from Stem CellsR01HL055417 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2000 to 2010
$3.2M
Lymphoid Tissue Inducer/NK22 Cells and Post-transplant Immune RecoveryR01AI100879 · NIAID · UNIVERSITY OF MINNESOTA · PI VERNERIS, MICHAEL R. · 2013 to 2017
$1.9M
NCI NIH HHS CA72669NCI NIH HHS P01 CA065493NCI NIH HHS P01 CA111412NCI NIH HHS P01CA65493NCI NIH HHS R01 CA072669NHLBI NIH HHS R01 HL055417NHLBI NIH HHS R01HL55417NIAID NIH HHS R01 AI100879PHS HHS P01067493
6 · The paper itself

Abstract

Death receptor 3 (DR3, TNFRSF25) is expressed by activated lymphocytes and signaling by its ligand, TL1A, enhances cytokine expression and proliferation. Recent studies show that DR3 is also present on murine type 2 innate lymphoid cells (ILC2s). Here, we show that DR3 is expressed by IL-22-producing human group 3 innate lymphoid cells (ILC3s). Stimulation of ILC3s with exogenous TL1A alone had no impact on cytokine production or proliferation. Addition of TL1A to IL-1β + IL-23 significantly enhanced the amount IL-22 produced by ILC3s as well as the percentage IL-22- and IL-8-producing cells. Addition of TL1A to IL-1β + IL-23 also augmented ILC3 proliferation. Mechanistically, this occurred through the upregulation of CD25 and responsiveness to IL-2 stimulation. The combination of TL1A, IL-1β+ IL-23, and IL-2 expanded ILC3s while IL-1β+ IL-23 did not increase proliferation above controls. After 2 weeks of expansion, ILC3s maintained their phenotype, transcription factor expression, and function (IL-22 production). These findings identify DR3 as a costimulatory molecule on ILC3s that could be exploited for ex vivo expansion and clinical use.

Indexed as

Immunity, InnateCell ProliferationCells, CulturedHumansInterleukin-1betaInterleukin-2Interleukin-22Interleukin-23 Subunit p19Interleukin-2 Receptor alpha SubunitInterleukin-8InterleukinsLymphocytesReceptors, Tumor Necrosis Factor, Member 25Tumor Necrosis Factor Ligand Superfamily Member 15Up-RegulationCXCL8 protein, humanIL1B protein, humanIL23A protein, humanIL2 protein, humanIL2RA protein, humanInterleukin-1betaInterleukin-2Interleukin-22Interleukin-23 Subunit p19Interleukin-2 Receptor alpha SubunitInterleukin-8InterleukinsReceptors, Tumor Necrosis Factor, Member 25TNFRSF25 protein, humanTNFSF15 protein, humanTumor Necrosis Factor Ligand Superfamily Member 15DR3HumanIL-22ILC3TL1A

Identifiers

PMID26046454
PMCPMC4595159
OpenAlexW2109509381

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.